A
Atea Pharmaceuticals
Innovative oral antiviral therapies transforming treatments for serious viral diseases
About Atea Pharmaceuticals
Atea Pharmaceuticals is a pioneering company in the discovery, development, and commercialization of oral direct-acting antiviral therapies. The company's most advanced drug candidate, bemnifosbuvir, is designed to treat severe viral infections, including Hepatitis C and COVID-19. Atea operates in the pharmaceutical market, focusing on patients affected by serious viral diseases. The business model revolves around developing innovative antiviral drugs and forming strategic collaborations, such as the partnership with Roche to develop and commercialize AT-527 for COVID-19 patients. Revenue is generated through the commercialization of these therapies and strategic partnerships. Atea serves healthcare providers and patients worldwide, aiming to transform the treatment landscape for viral infections.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2014
- Headquarters
- Boston, United States
- Listing
- IPO 2020
- Sector
- Biotech & Life Sciences
- Power Law
- Thoroughbred$100M+ revenue
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
RMI Partners
Series B and later3 investors entered at this stage
Bain Capital Life Sciences
Omega Funds
Perceptive Advisors
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Patents
25 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Atea Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Atea Pharmaceuticals on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.